Literature DB >> 24849482

The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy.

John Stover1, Chaitra Gopalappa, Mary Mahy, Meg C Doherty, Philippa J Easterbrook, Gundo Weiler, Peter D Ghys.   

Abstract

OBJECTIVES: The present study presents estimates of the number of people who would become newly eligible for antiretroviral therapy if all countries adopted the 2013 WHO treatment guidelines. It also shows the cost and impact that would result if coverage expanded to 80% of those eligible.
METHODS: The AIDS Impact Model (AIM) and the Goals model within the Spectrum modelling system were used for these estimates. Projections of costs and AIDS deaths are based on estimates for 116 low-income and middle-income countries. Projections of impact on HIV incidence are based on simulation modelling for 24 high burden countries, with the results scaled up to represent all low-income and middle-income countries.
RESULTS: If the 2013 guidelines were adopted universally, the number eligible for treatment would rise to 28.6 million in 2013. Achieving 80% coverage would mean 28 million on antiretroviral therapy by 2025, and would avert 2.9 million deaths and 3.9 million new infections from 2013 to 2025 compared with the 2010 guidelines.
CONCLUSION: The 2013 guidelines significantly expand the number eligible for treatment. Reaching those newly eligible will require additional resources, but is likely to produce significant benefits.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24849482     DOI: 10.1097/QAD.0000000000000235

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

1.  Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Authors:  Sara Lodi; Andrew Phillips; Roger Logan; Ashley Olson; Dominique Costagliola; Sophie Abgrall; Ard van Sighem; Peter Reiss; José M Miró; Elena Ferrer; Amy Justice; Neel Gandhi; Heiner C Bucher; Hansjakob Furrer; Santiago Moreno; Susana Monge; Giota Touloumi; Nikos Pantazis; Jonathan Sterne; Jessica G Young; Laurence Meyer; Rémonie Seng; Francois Dabis; Marie-Anne Vandehende; Santiago Pérez-Hoyos; Inma Jarrín; Sophie Jose; Caroline Sabin; Miguel A Hernán
Journal:  Lancet HIV       Date:  2015-07-07       Impact factor: 12.767

2.  Novel Predictors of Poor Retention Following a Down-Referral from a Hospital-Based Antiretroviral Therapy Program in South Africa.

Authors:  Jonathan Colasanti; Darius McDaniel; Brent Johnson; Carlos Del Rio; Henry Sunpath; Vincent C Marconi
Journal:  AIDS Res Hum Retroviruses       Date:  2015-12-09       Impact factor: 2.205

Review 3.  Embracing different approaches to estimating HIV incidence, prevalence and mortality.

Authors:  Timothy B Hallett; Basia Zaba; John Stover; Tim Brown; Emma Slaymaker; Simon Gregson; David P Wilson; Kelsey K Case
Journal:  AIDS       Date:  2014-11       Impact factor: 4.177

4.  The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.

Authors:  Arin Dutta; Catherine Barker; Ashley Kallarakal
Journal:  PLoS Med       Date:  2015-11-24       Impact factor: 11.069

5.  Fitting HIV Prevalence 1981 Onwards for Three Indian States Using the Goals Model and the Estimation and Projection Package.

Authors:  Tarun Bhatnagar; Tapati Dutta; John Stover; Sheela Godbole; Damodar Sahu; Kangusamy Boopathi; Shilpa Bembalkar; Kh Jitenkumar Singh; Rajat Goyal; Arvind Pandey; Sanjay M Mehendale
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

6.  HIV policy implementation in two health and demographic surveillance sites in Uganda: findings from a national policy review, health facility surveys and key informant interviews.

Authors:  Ellen McRobie; Alison Wringe; Jessica Nakiyingi-Miiro; Francis Kiweewa; Tom Lutalo; Gertrude Nakigozi; Jim Todd; Jeffrey William Eaton; Basia Zaba; Kathryn Church
Journal:  Implement Sci       Date:  2017-04-05       Impact factor: 7.327

7.  Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa.

Authors:  Matthew P Fox; Jacob Bor; Alana T Brennan; William B MacLeod; Mhairi Maskew; Wendy S Stevens; Sergio Carmona
Journal:  PLoS Med       Date:  2018-06-11       Impact factor: 11.613

8.  Impact of "test and treat" recommendations on eligibility for antiretroviral treatment: Cross sectional population survey data from three high HIV prevalence countries.

Authors:  Menard Laurent Chihana; Helena Huerga; Gilles Van Cutsem; Tom Ellman; Stephen Wanjala; Charles Masiku; Elisabeth Szumilin; Jean Francois Etard; Mary-Ann Davies; David Maman
Journal:  PLoS One       Date:  2018-11-26       Impact factor: 3.240

9.  Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda.

Authors:  Vivek Jain; Wei Chang; Dathan M Byonanebye; Asiphas Owaraganise; Ellon Twinomuhwezi; Gideon Amanyire; Douglas Black; Elliot Marseille; Moses R Kamya; Diane V Havlir; James G Kahn
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

10.  The costs of HIV treatment and care in Ghana.

Authors:  Evelinn Mikkelsen; Jan A C Hontelez; Justice Nonvignon; Sam Amon; Felix A Asante; Moses K Aikins; Julie van de Haterd; Rob Baltussen
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.